Neogenomics (NEO) Total Liabilities (2010 - 2026)

Neogenomics (NEO) has reported Total Liabilities for 17 consecutive years, with $517.8 million the latest figure, recorded in Q1 2026.

• Total Liabilities for Q1 2026 came in at $517.8 million, down 27.4% year-over-year; the trailing twelve-month figure through Mar 2026 was $517.8 million (down 27.4% YoY), and the FY2025 annual result was $523.3 million, down 28.87% from the prior year.
• Total Liabilities was $517.8 million for Q1 2026 at Neogenomics, down from $523.3 million in the prior quarter.
• Over five years, Total Liabilities peaked at $754.5 million in Q1 2022 and troughed at $517.8 million in Q1 2026.
• Average Total Liabilities over 5 years is $686.8 million, with a median of $732.9 million recorded in 2024.
• Year-over-year, Total Liabilities grew 15.96% in 2022 and fell 28.87% in 2025.
• Over 5 years, Total Liabilities stood at $742.0 million in 2022, then slipped by 0.31% to $739.7 million in 2023, then decreased by 0.54% to $735.7 million in 2024, then dropped by 28.87% to $523.3 million in 2025, then declined by 1.05% to $517.8 million in 2026.
• Per Business Quant data, the three most recent Total Liabilities figures were $517.8 million in Q1 2026, $523.3 million in Q4 2025, and $536.5 million in Q3 2025.